Can Pheochromocytoma Cause Hypertension?
Yes, pheochromocytoma definitively causes hypertension—approximately 95% of patients with pheochromocytoma present with elevated blood pressure, with 50% experiencing sustained hypertension and 50% having paroxysmal (episodic) hypertension. 1, 2
Mechanism of Hypertension in Pheochromocytoma
Pheochromocytoma causes hypertension through excessive catecholamine secretion (norepinephrine, epinephrine, and dopamine) from chromaffin cell tumors of the adrenal medulla or sympathetic ganglia. 1
The degree of blood pressure elevation and the pattern (sustained versus paroxysmal) correlate directly with the level of norepinephrine secretion by the tumor. 1
Pheochromocytoma is characterized by marked blood pressure variability, which constitutes an independent cardiovascular risk factor beyond the elevated blood pressure itself, significantly increasing morbidity and mortality. 1
Clinical Significance and Prevalence
While pheochromocytoma accounts for only 0.1% to 0.6% of hypertensive patients in general ambulatory populations, it represents a critical secondary cause of resistant hypertension. 1
In patients with resistant hypertension (blood pressure >140/90 mmHg despite optimal doses of ≥3 antihypertensive medications including a diuretic), pheochromocytoma should always be considered in the differential diagnosis. 1
The classic triad of episodic severe headache, palpitations, and diaphoresis (sweating) in a hypertensive patient has 90% diagnostic specificity and 93.8% sensitivity for pheochromocytoma. 1, 2
Critical Diagnostic Pitfalls
Despite improved diagnostic techniques, there remains an average 3-year delay between initial symptoms and final diagnosis, and many cases are completely missed—autopsy studies reveal that pheochromocytoma contributed to 55% of deaths in cases where the tumor was not suspected during life (75% of cases). 1, 2
This diagnostic delay has devastating consequences because untreated pheochromocytoma can cause life-threatening complications including hypertensive crisis, stroke, myocardial infarction, cardiomyopathy, cardiac arrest, or sudden death. 2
Screening Recommendations
When to screen for pheochromocytoma in hypertensive patients:
- Resistant hypertension despite multiple antihypertensive agents 1
- Paroxysmal hypertension with the classic triad (headache, palpitations, sweating) 1, 2
- Early-onset hypertension (age <30 years) 1
- Hypertension with significant blood pressure variability or lability 1
- Family history of pheochromocytoma or hereditary syndromes (MEN2, VHL, NF1, SDHx mutations) 2
- Incidentally discovered adrenal mass 1
- Hypertension with unexplained hypokalemia or muscle weakness 1
Diagnostic Approach
Plasma free metanephrines (normetanephrine and metanephrine) are the best screening test, with 99% sensitivity and 89% specificity—this should be the first-line biochemical test. 1, 2
For optimal accuracy, plasma free metanephrines should ideally be collected from an indwelling venous catheter after the patient has been lying supine for 30 minutes to minimize false positives. 2
If plasma testing is equivocal (less than fourfold elevation), perform 24-hour urine collection for fractionated metanephrines and catecholamines. 1, 2
After biochemical confirmation, proceed to imaging with MRI (preferred over CT due to risk of hypertensive crisis with IV contrast) to localize the tumor. 1, 2
Post-Surgical Outcomes
While surgical excision is the definitive treatment, pheochromocytoma should not be unreservedly considered a surgically remediable cause of hypertension—Kaplan-Meier estimates show that only 74% and 45% of patients remain hypertension-free at 5 and 10 years post-surgery, respectively. 3
Tumor recurrence occurs in approximately 17% of patients, with pheochromocytoma-free survival rates of 92% at 5 years and 80% at 10 years, necessitating lifelong biochemical surveillance. 3
Familial pheochromocytoma and low plasma epinephrine-to-total catecholamine ratio are independent predictors of tumor recurrence, while familial hypertension and older age predict persistent hypertension after surgery. 3